Solid-phase synthesis of neuroactive spider-wasp hybrid toxin analogues using a backbone amide linker

Tetrahedron Letters

Volumn 48, Issue 3, 2007, Pages 405-408

  Olsen, Christian A ^a   Witt, Matthias ^b   Franzyk, Henrik ^a   Jaroszewski, Jerzy W ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BRUKER DALTONIK GMBH   (Germany)

Author keywords

BAL resin; Natural product analogues; Solid phase synthesis; Spider toxins

Indexed keywords

AMIDE; IONOTROPIC RECEPTOR; LIGAND; POLYAMINE DERIVATIVE; RESIN; TOXIN; VENOM;

AMINATION; ARTICLE; CENTRAL NERVOUS SYSTEM; HYBRID; PERIPHERAL NERVOUS SYSTEM; QUANTUM YIELD; REACTION ANALYSIS; REDUCTION; SOLID; SPIDER; STRUCTURE ACTIVITY RELATION; TOXIN SYNTHESIS;

ARANEAE; POMPILIDAE;

EID: 33845454863     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2006.11.074     Document Type: Article

References (32)

1. Adams M.E., Carney R.L., Enderlin F.E., Fu E.T., Jarema M.A., Li J.P., Miller C.A., Schooley D.A., Shapiro M.J., and Venema V.J. Biochem. Biophys. Res. Commun. 148 (1987) 678-683
2. Eldefrawi A.T., Eldefrawi M.E., Konno K., Mansour N.A., Nakanishi K., Eugene O., and Usherwood P.N.R. Proc. Natl. Acad. Sci. USA 85 (1988) 4910-4913
3. Piek T., Fokkens R.H., Karst H., Kruk C., Lind A., van Marle J., and Tong Y.C. In: Lunt G.G. (Ed). Neurotox 8: Molecular Basis of Drug and Pesticide Action (1988), Elsevier, Amsterdam 61-76
4. Scott R.H., Sutton K.G., and Dolphin A.C. Trends Neurosci. 16 (1993) 153-160
5. Mueller A.L., Roeloffs R., and Jackson H. Alkaloids 46 (1995) 63-94
6. For reviews, see:. Strømgaard K., Andersen K., Krogsgaard-Larsen P., and Jaroszewski J.W. Mini Rev. Med. Chem. 1 (2001) 317-338
7. Strømgaard K., and Mellor I.R. Med. Res. Rev. 24 (2004) 589-620
8. Mellor I.R., and Usherwood P.N.R. Toxicon 43 (2004) 493-508
9. Lipton S.A. Nat. Rev. Drug Discov. 5 (2006) 160-170
10. Cohen S.S. A Guide to Polyamines (1998), Oxford University Press, New York
11. Olsen C.A., Mellor I.R., Wellendorph P., Usherwood P.N.R., Witt M., Franzyk H., and Jaroszewski J.W. ChemMedChem 1 (2006) 303-305
12. Mellor I.R., Brier T.J., Pluteanu F., Strømgaard K., Saghyan A., Eldursi N., Brierley M.J., Andersen K., Jaroszewski J.W., Krogsgaard-Larsen P., and Usherwood P.N.R. Neuropharmacology 44 (2002) 70-80
13. For reviews, see:. Karigiannis G., and Papaioannou D. Eur. J. Org. Chem. (2000) 1841-1863
14. Kuksa V., Buchan R., and Lin P.K.T. Synthesis-Stuttgart (2000) 1189-1207
15. For a comprehensive review of available methods for formation of the amino functionality on solid phase, see:. Olsen C.A., Franzyk H., and Jaroszewski J.W. Synthesis-Stuttgart (2005) 2631-2653
16. Strømgaard K., Brier T.J., Andersen K., Mellor I.R., Saghyan A., Tikhonov D., Usherwood P.N.R., Krogsgaard-Larsen P., and Jaroszewski J.W. J. Med. Chem. 43 (2000) 4526-4533
17. Jørgensen M.R., Olsen C.A., Mellor I.R., Usherwood P.N.R., Witt M., Franzyk H., and Jaroszewski J.W. J. Med. Chem. 48 (2005) 56-70
18. Jørgensen M.R., Jaroszewski J.W., Witt M., and Franzyk H. Synthesis-Stuttgart (2005) 2687-2694
19. Bycroft B.W., Chan W.C., Hone N.D., Millington S., and Nash I.A. J. Am. Chem. Soc. 116 (1994) 7415-7416
20. Olsen C.A., Jørgensen M.R., Hansen S.H., Witt M., Jaroszewski J.W., and Franzyk H. Org. Lett. 7 (2005) 1703-1706
21. Manov N., and Bienz S. Tetrahedron 57 (2001) 7893-7898
22. Manov N., Tzouros M., Chesnov S., Bigler L., and Bienz S. Helv. Chim. Acta 85 (2002) 2827-2846
23. Jensen K.J., Alsina J., Songster M.F., Vágner J., Albericio F., and Barany G. J. Am. Chem. Soc. 120 (1998) 5441-5452
24. For preparation and characterization of 5a and 5b, see Ref. 12.
25. Conditions were inspired by Korínek, M.; Dudic, M.; Havránek, M., poster presented at PacifiChem 2005, Honolulu, Hawaii, USA.
26. Coste J., Le-Nguyen D., and Castro B. Tetrahedron Lett. 31 (1990) 205-208
27. Carpino L.A., and El-Faham A. J. Am. Chem. Soc. 117 (1995) 5401-5402
28. Olsen C.A., Witt M., Jaroszewski J.W., and Franzyk H. Org. Lett. 5 (2003) 4183-4185
29. + at m/z 590.43883; found, 590.43869; ΔM = 0.24 ppm.
30. 215 nm (∼80%), which is in contrast to the excellent purities (>99%) obtained after isolation by preparative RP-HPLC.
31. Goodnow Jr. R., Konno K., Niwa M., Kallimopoulos T., Bukownik R., Lenares D., and Nakanishi K. Tetrahedron 46 (1990) 3267-3286
32. Nakanishi K., Goodnow Jr. R., Konno K., Niwa M., Bukownik R., Kallimopoulos T., Usherwood P.N.R., Eldefrawi A.T., and Eldefrawi M.E. Pure Appl. Chem. 62 (1990) 1223-1230